Roxithromycin induced hypersensitivity pneumonitis.
Chew
G Y J
GY
Hawkins
C A
CA
Cherian
M
M
Hurwitz
M
M
D000542:Alveolitis, Extrinsic Allergic / Q000139:chemically induced* / Q000473:pathology; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D004359:Drug Therapy, Combination; D005260:Female; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D017336:Loratadine / Q000627:therapeutic use; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D011899:Ranitidine / Q000627:therapeutic use; D015575:Roxithromycin / Q000009:adverse effects*; D016896:Treatment Outcome
D018926:Anti-Allergic Agents; D000900:Anti-Bacterial Agents; D006635:Histamine H2 Antagonists; D015575:Roxithromycin; D017336:Loratadine; D011899:Ranitidine; D011239:Prednisolone